Quick answer
Keycell-IM is an immune cell therapeutic product developed by EHL BIO using advanced technologies to isolate and culture multiple types of immune cells (such as T cells, NK cells) from a patient's own blood. This innovative technique in Korea aims to support the body's management of abnormal cells and enhance quality of life according to EHL team assessments.
Key takeaways
- Keycell-IM is derived from the patient's own blood (Autologous) and cultured using EHL BIO's proprietary technology in Korea.
- Combines multiple immune cell types, including T cells, NK cells, and Dendritic cells, for restorative efficacy.
- Apheresis technology allows harvesting 30 times more cells than usual, enabling one blood draw to support continuous care as appropriate.
- Production and cryopreservation are conducted under Korean GMP standards to ensure quality and hygiene.
Keycell-IM Innovation in Health Promotion
Immune Cell Therapeutics, specifically Keycell-IM, represents a core research pillar at EHL BIO, focusing on leveraging the body's natural mechanisms. This product is created by taking a patient's blood and subjecting it to advanced isolation and cultivation of specialized immune cells, including T cells, NK cells, Dendritic cells, and iNKT cells using advanced technology in Korea.
The primary goal of Keycell-IM is to manage residual abnormal cells following primary care and support internal strength, which is essential for recovery goals and a patient's quality of life. By using autologous cells, it minimizes concerns regarding negative immune responses. This approach serves as a positive alternative that supports the body according to EHL team assessments.
Advanced Harvesting and Cultivation Technology in Korea
EHL BIO's distinction in developing Keycell-IM lies in the application of Apheresis technology for cell harvesting, which allows for the isolation of immune cells at 30 times the volume of standard collection. This technique enhances cultivation efficiency and benefits patients, as the high concentration allows a single draw to be utilized as planned.
Furthermore, EHL BIO is a leader in multi-cell therapy technology in Korea, combining various types of immune cells to broaden the scope of targeting abnormal cells. All processes occur within a research center equipped with modern analytical tools, ensuring every cell batch meets recovery goals and quality of life standards as planned by the medical team.
Keycell-IM is an innovation that harnesses the power of your own immune system for recovery goals and a better quality of life.
Korean GMP Safety Standards
Quality and safety are at the heart of Keycell-IM research. EHL BIO was certified as a 'Human Cell Management Business' by the Korean Ministry of Food and Drug Safety (MFDS) under the Advanced Regenerative Bio Act. Our GMP (Good Manufacturing Practices) facility has a robust production capacity.
The cultivation environment is strictly controlled within Clean Room Class 100 settings, featuring HEPA filtration systems to ensure cleanliness at every stage. This includes cryopreservation technology at low temperatures to maintain the integrity of immune cells until needed. These standards confirm the reliability of EHL BIO's processes in Korea.
Collaboration Network and Service Process
EHL BIO emphasizes integrated research through a network of partner hospitals in Korea. For clients from Thailand, EHL Thailand provides a dedicated coordination team to facilitate every step, beginning with a consultation for medical record evaluation.
Once the recovery plan is approved, travel arrangements are made to EHL Cell Clinic in Seoul for physical examination and blood collection via Apheresis. The cells are then cultured in our high-standard GMP center. Upon completion, the patient receives personalized care as planned, followed by continuous monitoring after returning to Thailand to support recovery goals and long-term quality of life.
Frequently asked questions
How does Keycell-IM differ from general immunotherapy?
Keycell-IM utilizes a multi-cell approach combining various immune cells like NK and T cells, and employs Apheresis technology to harvest large volumes of cells, representing advanced techniques in Korea.
How safe and appropriate is Keycell-IM care?
It is highly appropriate and positive for the body because it uses the patient's own cells (Autologous), reducing concerns about internal rejection, and is produced under strict Korean GMP standards.
What are the recovery goals and quality of life expectations for Keycell-IM?
It focuses on strengthening the immune system to manage abnormal cells and enhancing bodily strength for a better quality of life as assessed by EHL BIO medical team in Korea. EHL Thailand will assist in coordinating all steps.
Related conditions
Based on EHL BIO information: EHL BIO · EHL BIO · EHL BIO · EHL BIO. Each care plan follows an individual EHL assessment.
